TY - JOUR AU - Wang Hui-fang AU - Wang Yi-xuan AU - Zhou Yu-ping AU - Wei Yun-peng AU - Yan Yi AU - Zhang Ze-jian AU - Jing Zhi-cheng PY - 2022 TI - Protein O -GlcNAcylation in cardiovascular diseases JF - Acta Pharmacologica Sinica; Vol 44, No 1 (January 2023): Acta Pharmacologica Sinica Y2 - 2022 KW - N2 - O -GlcNAcylation is a post-translational modification of protein in response to genetic variations or environmental factors, which is controlled by two highly conserved enzymes, i.e. O-GlcNAc transferase (OGT) and protein O-GlcNAcase (OGA). Protein O -GlcNAcylation mainly occurs in the cytoplasm, nucleus, and mitochondrion, and it is ubiquitously implicated in the development of cardiovascular disease (CVD). Alterations of O -GlcNAcylation could cause massive metabolic imbalance and affect cardiovascular function, but the role of O -GlcNAcylation in CVD remains controversial. That is, acutely increased O -GlcNAcylation is an adaptive heart response, which temporarily protects cardiac function. While it is harmful to cardiomyocytes if O -GlcNAcylation levels remain high in chronic conditions or in the long run. The underlying mechanisms include regulation of transcription, energy metabolism, and other signal transduction reactions induced by O -GlcNAcylation. In this review, we will focus on the interactions between protein O -GlcNAcylation and CVD, and discuss the potential molecular mechanisms that may be able to pave a new avenue for the treatment of cardiovascular events. UR - http://www.chinaphar.com/article/view/10735